Overview
Dr. Sharon Castellino is the director of the Leukemia/Lymphoma (LL) program for the Aflac Cancer and Blood Disorders Center and also serves as the co-leader of the LL biorepository and vice-chair of the Aflac Precision Medicine Program protocol.
Dr. Castellino’s overarching research is related to outcomes and late effects in Pediatric Leukemia and Lymphoma patients and survivors, with a focus on Hodgkin Lymphoma (HL).
She is the study chair for two Children’s Oncology Group (COG) trials for advanced stage HL. She also has leadership within the COG guidelines task force on survivorship care, with expertise in understanding hepatic late effects in childhood cancer.
Her investigator initiated research has been in retrospective data analyses of large datasets, with a focus on examining disparities in outcomes. In addition, Dr. Castellino has examined biomarkers of cardiovascular injury and has interests in cardio-oncology.
Nick DeGroote, MPH, Research epidemiologist
Current Project: Use of IVIG in pediatric B-ALL; Real world use of data in novel agents
Email: nicholas.degroote@choa.org
Himalee Sabnis, MD, Assistant Professor, Pediatric Hematology/Oncology
Current Project: Late effects in pediatric patients who received tyrosine kinase inhibitors
Email: himalee.sabnis@choa.org
Tamara Miller, MD, MSCE, Assistant Professor, Pediatric Hematology/Oncology
Current Project: Current Outcomes in pediatric ALL patients
Xu Ji, PhD, Health Services Researcher
Holly Edington, MD, Fellow, Pediatric Hematology/Oncology
Education: University of North Carolina, Medical School, University of Toledo College of Medicine and Life Sciences, Residency, Eastern Virginia Medical School/Children’s Hospital of the King’s Daughters, Fellowship, Hematology/Oncology, Emory University/Children’s Healthcare of Atlanta
Current Project: Immunoglobulin administration and hypogammaglobulinemia during pediatric acute leukemia therapy
Fun Fact: I am a Big Ten college football fan.
Email: holly.edington@choa.org
Rebecca Lewis, MPH
Education: Undergraduate, University of Virginia, Charlottesville VA, Masters, Rollins School of Public Health, Emory University
Current Project: Late effects in pediatric patients who received tyrosine kinase inhibitors; validating cardiac care in childhood cancer survivors
Karen Effinger, MD, MSc, Assistant Professor, Pediatrics, Emory University, Aflac Cancer and Blood Disorders Center
Lane Miller, MD, MSc, Fellow, Pediatric Hematology/Oncology, Aflac Cancer and Blood Disorders Center
Justine Kahn, MD, MSc, Assistant Professor, Columbia University
Emily Silverman, Medical student, NYU Class of 2024
West ZE, *Castellino SM, Monroe C, Thomas AS, McCracken C, Miller TP. Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia. Leuk Lymphoma 2020 Dec1:1-14 PMID 33258395(*co-first authors)
Castellino SM, Parsons SK, Kelly KM. Closing the survivorship gap in children and adolescents with Hodgkin Lymphoma. British J Haematol, 2019 Dec; 187(5): 573-58. PMID:31566730
Kahn J, Kelly KM, Pei, Q, Bush R, Friedman DL, Keller FG, Bhatia A, Henderson TO, Schwartz CL, Castellino, SM. Survival by race and ethnicity in children and adolescents with Hodgkin Lymphoma: A Children’s Oncology Group Study. J Clin Oncol, 2019 Nov 10;37(32):3009-3017. PMID:31539308
Blum KA, Keller FG, Castellino S, Phan A, Flowers CR. Incidence and outcomes of lymphoid malignancies in adolescent and young adult (AYA) patients in the United States. Br J Haematol. 2018 Nov; 183(3):385-399 PMID: 30095154
Keller FK, Castellino SM, Chen L, Pei Q, Voss SD, McCarten KM, Senn SL, Buxton A, Bush R, Constine LS, Schwartz CL. Results of the AHOD0431 Trial of Response Adapted Therapy and a Salvage Strategy for Limited-Stage Classical Hodgkin Lymphoma: A Report from the Children’s Oncology Group. Cancer 2018 Aug; 124(15):3210-3219. PMID:29738613
Parsons SK, Kelly MJ, Cohen JT, Castellino SM, Henderson TO, Kelly KM, Keller FG, Henzer TJ, Kumar AJ, Johnson P, Meyer RM, Radford J, Raemaekers J, Hodgson DC, Evens AM. Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. Br J Haematol. 2018 Jul; 182(2):212-221. PMID:29707774
Shaw PH, Reed DR, Yeager N, Zebrack B, Castellino SM, Bleyer A. Adolescent and Young Adult (AYA) Oncology in the United States: A Specialty in its Late Adolescence. J Pediatr Hematol Oncol. 2015 Apr;37(3):161-9. PMID: 25757020
Geiger AM, Castellino SM, Tooze JA, Altschuler A, Month S, Mertens AC, Nekhlyudov N, Greene SM. Potential role of community-based healthcare system data in research on survivors of adolescent and young adult cancer. J Adolesc Young Adult Oncol 2013 Jun 2(2):53-58. PMID 23781401
Geiger AM, Castellino SM. Delineating the Age Ranges Used to Define Adolescents and Young Adults. J Clin Oncol. 2011 Jun 1;29(16):e492-3. PMID: 21482981
Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, Stovall M, Robison LL, Hudson MM. Morbidity and Mortality in Long-Term Survivors of Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study. Blood. 2011 Feb 10;117 (6):1806-16.PMID: 21037086
Metzger M, Castellino SM, Hudson MM, Rai SN, Kaste SC, Krasin MJ, Kun LE, Pui C, Howard SC. Effect of Race on the Outcome of Pediatric Patients with Hodgkin Lymphoma. J Clin Oncol 2008; 26(8):1282-8. PMID:18323551
Castellino SM, Casillas J, Hudson M, Mertens A, Whitton J, Brooks S, Zeltzer L, Ablin A, Castleberry R, Hobbie W, Kaste S, Robison L, Oeffinger K. Minority adult survivors of childhood cancer: a comparison of long-term outcomes, health care utilization and health related behaviors from the childhood cancer survivor study (CCSS). J Clin Oncol 2005; 23:6499-507. PMID:16170159
Private Foundation Funding:
CURE Childhood Cancer - 7/1/2017-6/30/2022
Aflac Precision Medicine: An investigation to create a systematic institutional approach to seek novel molecular abnormalities and potential therapy targets for all high risk cancer patients from diagnosis onward
Role: Co-I; Protocol Vice-Chair
PI: Graham
National Institutes of Health/Contracts:
NIH-R03CA259665-01
Understanding the impact of the Affordable Care Act on cancer treatment and outcomes for adolescents and young adults (AYA)
Role: Co-PI
PI: Ji
NIH-U01CA246567
Implementation of a Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors
Role: Co-I
PI: Landier/Klosky
U48DP006377-02-00
Mertens: SIP 20-004. Effect of Survivorship Care Plans on Cancer Mortality
Role: Co-I
PI: Kegler
COG-U10CA98543 - 12/1/2014-Present
AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents
Role: Study Chair
PI: Adamson
COG-U10CA98543 - 6/1/2019-5/31/2023
SWOG S1826: A Phase III Randomized Study of Nivolumab or Brentuximab Vedotin plus AVD in Patients (Age >/=12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Role: Pediatric Study Chair (Overall Study Chair, Alex Herrera)
PI: Adamson
SurvivorLink - 10/1/2018-9/30/2023
Scalability of an Electronic Personal Health Record for Cancer Survivors and Caregivers at Pediatric Cancer Centers
Role: Advisory Board
Co-PI: Mertens/Escoffery
K07CA211956-01A1 - 09/21/2017-08/31/2022
The goal of this project is to use electronic medical record (EMR) data to capture adverse events of therapy for pediatric cancer at two large children’s hospitals and to use EMR data to describe the incidence and risk factors of acute kidney injury in children receiving therapy to treat leukemia.
Role: Mentor Team
PI: Tamara Miller
Bristol-Myers Squibb - 1/2016-10/1/2019
1LETKI: Late Effects after Tyrosine Kinase Inhibitor Therapy in children and adolescents
Role: Mentor/CoPI
Honoree, Researcher Appreciation Day, Emory School of Medicine, Atlanta, GA, Sept. 2020